Trials / Completed
CompletedNCT02083289
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-9054 | |
| DRUG | Latanoprost |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-12-01
- First posted
- 2014-03-11
- Last updated
- 2016-02-25
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02083289. Inclusion in this directory is not an endorsement.